


SB-612111

Cat. No.:	HY-18618
CAS No.:	371980-98-2
Molecular Formula:	C ₂₄ H ₂₉ Cl ₂ NO
Molecular Weight:	418.4
Target:	Opioid Receptor
Pathway:	GPCR/G Protein; Neuronal Signaling
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	SB-612111 is a novel and potent opiate receptor-like orphan receptor (ORL-1) antagonist with a high affinity for hORL-1 (K _i = 0.33 nM). SB-612111 exhibits selectivity for μ-, κ- and δ-receptors with K _i values of 57.6 nM, 160.5 nM and 2109 nM, respectively. SB-612111 effectively antagonizes the pronociceptive action of Nociceptin (HY-P0183) in an acute pain model ^[1] .								
IC₅₀ & Target	K _i : 0.33 nM (hORL-1) K _i : 57.6 nM (μ-receptor); 160.5 nM (κ-receptor); 2109 nM (δ-receptor) ^[1]								
In Vivo	<p>SB-612111 (intravenous injection; 0.6-10 nmol/mouse) antagonize nociceptin-induced thermal hyperalgesia in a dose-dependent manner with an ED₅₀ of 0.62 mg/kg^[1].</p> <p>SB-612111 (intravenous injection; 0.1-5 mg/kg) causes a significant inhibition of the carrageenan-induced reduction in paw withdrawal latencies in rat, however, untreated paw are unaffected^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>Male rats^[1]</td> </tr> <tr> <td>Dosage:</td> <td>0.1 mg/kg, 0.3 mg/kg, 1 mg/kg, 3 mg/kg, 5 mg/kg</td> </tr> <tr> <td>Administration:</td> <td>Intravenous injection; single dose</td> </tr> <tr> <td>Result:</td> <td>Had antihyperalgesic effects on carrageenan-induced rat paw.</td> </tr> </table>	Animal Model:	Male rats ^[1]	Dosage:	0.1 mg/kg, 0.3 mg/kg, 1 mg/kg, 3 mg/kg, 5 mg/kg	Administration:	Intravenous injection; single dose	Result:	Had antihyperalgesic effects on carrageenan-induced rat paw.
Animal Model:	Male rats ^[1]								
Dosage:	0.1 mg/kg, 0.3 mg/kg, 1 mg/kg, 3 mg/kg, 5 mg/kg								
Administration:	Intravenous injection; single dose								
Result:	Had antihyperalgesic effects on carrageenan-induced rat paw.								

REFERENCES

[1]. Paola F Zarin, et al. Modification of Nociception and Morphine Tolerance by the Selective Opiate Receptor-Like Orphan Receptor Antagonist (-)-cis-1-methyl-7-[[4-(2,6-dichlorophenyl)piperidin-1-yl]methyl]-6,7,8,9-tetrahydro-5H-benzocyclohepten-5-ol (SB-612111). J Pharmacol Exp Ther. 2004 Feb;308(2):454-61.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA